Successful treatment of multiply relapsed lymphoma with rituximab as a single agent.
The treatment of non-Hodgkin lymphoma (NHL) is an example of the successful therapy of cancer in children; the cure rate overall at approximately 80%. Unfortunately, relapsed NHL has a dismal prognosis, and the customary treatment is highly toxic chemotherapy followed by hematopoietic stem cell transplantation (HSCT). A child with relapsed T-cell rich B-NHL was treated with rituximab alone. This was delivered in eight doses after the recurrence of disease after high-dose chemotherapy and allogenic HSCT that was undertaken for the first relapse. Eight years after the last dose of rituximab he remains in complete remission.
Alasaad
Tariq
T
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Barr
Ronald
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002648:Child; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008297:Male; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab